MEKTOVI

PeakSM

binimetinib

NDAORALTABLET
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cell-free assays as well as…

Indications (1)

Clinical Trials (5)

NCT07092410Phase 4Not Yet Recruiting

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Started Aug 2025
101 enrolled
Melanoma BRAF V600E/K Mutated
NCT07022457N/ARecruiting

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Started Jul 2025
50 enrolled
Metastatic Melanoma, BRAF V600 Mutation Positive
NCT06887088Phase 2Recruiting

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Started May 2025
33 enrolled
Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
NCT06207656Phase 2Recruiting

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

Started Apr 2024
70 enrolled
Colorectal Cancer
NCT05954546N/ACompleted

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Started Jul 2023
275 enrolled
Metastatic Melanoma

Loss of Exclusivity

LOE Date
Oct 18, 2033
92 months away
Patent Expiry
Oct 18, 2033
Exclusivity Expiry
Oct 11, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
7777050
Mar 13, 2026
SubstanceProduct
9850229
Aug 27, 2030
U-2333
10005761
Aug 27, 2030
U-3737
9314464
Jul 4, 2031
U-3737
9562016
Oct 18, 2033
SubstanceProduct